Leerink Partners Upgrades Abbott Laboratories to Outperform, Announces $124 Price Target

Benzinga · 2d ago
Leerink Partners analyst Mike Kratky upgrades Abbott Laboratories (NYSE:ABT) from Market Perform to Outperform and announces $124 price target.